Open an account

Scinai Immunotherapeutics

SCNI · NASDAQ

$0.6813−$0.0687 (−9.16%)TodayMarket closed ·
Prev close $0.75

About SCNI

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Employees
45
Headquarters
Jerusalem
Listed
Jun 7, 2007
Sector
Health Care
Industry
Biotechnology
Website
scinai.com

SCNI key statistics

Market cap
427.52K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.28M
Volume
90.93K
Open price
$0.74
High today
$0.74
Low today
$0.6726
52 Week high
$15.50
52 Week low
$0.66

Scinai Immunotherapeutics (SCNI) at a glance

Scinai Immunotherapeutics (SCNI) last traded at $0.6813, with a market cap of 427.52K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.6726 and $0.74. The current price is 1.3% above the day's low and 7.9% below its high.

Volume so far is 90.93K shares, below the average of 4.28M shares a day.

Over the past year Scinai Immunotherapeutics has ranged from $0.66 to $15.50, and now sits 0% of the way up that range.

Scinai Immunotherapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q4 FY23 it reported -$47.00 per share against an estimate of -$63.24.

SCNI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 99.0% on average.

  1. Q4 FY21: reported -$270.00 per share against an estimate of -$86.70
  2. Q1 FY22: reported -$200.00 per share against an estimate of -$102.00
  3. Q2 FY22: reported -$20.00 per share against an estimate of -$107.10
  4. Q3 FY22: reported $1.00 per share against an estimate of -$10.20
  5. Q1 FY23: reported -$109.00 per share against an estimate of -$74.46
  6. Q2 FY23: reported -$111.00 per share against an estimate of -$92.82
  7. Q3 FY23: reported $80.00 per share against an estimate of -$100.98
  8. Q4 FY23: reported -$47.00 per share against an estimate of -$63.24

SCNI news

  • Press releasePRNewswire

    Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing

  • Press releasePRNewswire

    Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement

  • Press releasePRNewswire

    Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement

  • Vandana Singh

    Why Is Scinai Immunotherapeutics Stock Gaining Tuesday?

  • Press releasePRNewswire

    Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

  • Press releasePRNewswire

    Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

  • Avi Kapoor

    Nasdaq Down Over 200 Points; Cellectis Shares Plunge

  • Press releasePRNewswire

    Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

Similar companies

Companies in the same industry as Scinai Immunotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.